Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 543

Results For "C"

9223 News Found

AIIA launches 6-week long Ayurveda Day 2022 Programme
News | September 13, 2022

AIIA launches 6-week long Ayurveda Day 2022 Programme

The programme will see participation from various ministries of the Government of India with the aim of 3Js – Jan Sandesh, Jan Bhagidari, and Jan Aandolan.


AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData
Drug Approval | September 13, 2022

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.


Auretics Introduces its range of ayurvedic products
News | September 13, 2022

Auretics Introduces its range of ayurvedic products

This includes Madhurodhi, HBP Care & LBP Care for sugar & BP patients


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Clinical Trials | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


We will vaccinate 100% of the animals by 2025: Narendra Modi
Policy | September 13, 2022

We will vaccinate 100% of the animals by 2025: Narendra Modi

The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals


Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
Clinical Trials | September 12, 2022

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Clinical Trials | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022


Thalassemia Sickle Cell Society receives 200000th blood units
Healthcare | September 12, 2022

Thalassemia Sickle Cell Society receives 200000th blood units

Thalassemia and Sickle Cell Society (TSCS) always stands forefront in providing blood transfusion free of cost for Thalassemia Blood disorders patients


Zenara Pharma launches the first generic of Paxlovid for COVID-19 in India
News | September 12, 2022

Zenara Pharma launches the first generic of Paxlovid for COVID-19 in India

Pfizer’s Paxlovid is approved by US FDA for COVID treatment


WuXi STA opens a new sterile lipid nanoparticle formulation facility
News | September 11, 2022

WuXi STA opens a new sterile lipid nanoparticle formulation facility

This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform